Date: 2017-01-09
Type of information: Grant
Company: Kymab (UK)
Investors: Bill & Melinda Gates Foundation (USA)
Amount: $9 million
Funding type: grant
Planned used: The grant will be used to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
Others:
- • On January 9, 2017, Kymab announced that it has received a $9 million grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
- The Gates Foundation will provide the funding over the next three years to enable Kymab to strengthen its work to develop treatments and vaccines for infectious disease using its Kymouse™ antibody platform. The Gates Foundation will have the rights to develop and distribute these products to low-income countries and Kymab will retain rights to commercialise the products in developed countries. This funding builds on Kymab’s established work, allowing the parties to further collaborate in the future.
- Kymab has been working with the Gates Foundation and its partners since 2014 on programmes in diseases such as malaria, HIV, and Typhoid; together, these diseases result in more than one million deaths each year. In addition to the new investment in Kymab’s research, the Foundation has also invested $30m in Kymab’s Series B and Series C financing, which supported development of the Kymouse™ platform.
- The extension of the collaboration with the Gates Foundation follows publication in Science on 8 September, 2016 of new findings which demonstrated that Kymouse™ is an effective platform for discovering and testing novel vaccines and therapeutics for infectious diseases including HIV 1.
Therapeutic area: Infectious diseases
Is general: Yes
